Compugen 
Welcome,         Profile    Billing    Logout  
 5 Products   0 Diseases  5 Products   30 Trials   380 News 
33 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bapotulimab (BAY 1905254) / Compugen
KEYNOTE-920, NCT03666273: Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

Completed
1
60
US
Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
Bayer, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
06/23
05/24
COM902 / Compugen
CPG-02-101, NCT04354246: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Checkmark Data from trial for solid tumors at SITC 2021
Nov 2021 - Nov 2021: Data from trial for solid tumors at SITC 2021
Checkmark First patient dosed in combination with COM701 in patients with advanced malignancies
Jul 2021 - Jul 2021: First patient dosed in combination with COM701 in patients with advanced malignancies
Active, not recruiting
1
110
US
Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Compugen Ltd
Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
12/25
12/25
COM701 / Compugen
NCT04570839: COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Checkmark Data from a trial in combination with COM701 and BMS-986207 for platinum resistant ovarian cancer at ESMO-IO 2022
Dec 2022 - Dec 2022: Data from a trial in combination with COM701 and BMS-986207 for platinum resistant ovarian cancer at ESMO-IO 2022
Checkmark Data from trial in combination with opdivo for solid tumors at SITC 2021
Nov 2021 - Nov 2021: Data from trial in combination with opdivo for solid tumors at SITC 2021
Checkmark First patient dosed P1/2 study in the triple combination with Opdivo and BMS-986207 for solid tumor
More
Completed
1/2
48
US
COM701 in combination with BMS-986207 and nivolumab.
Compugen Ltd, Bristol-Myers Squibb
Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
05/24
05/24
NCT06888921: A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

Recruiting
1/2
60
US
COM701, Normal Saline
Compugen Ltd
Ovarian Cancer, Ovarian Cancer Recurrent
03/27
03/27
NCT03667716: COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Checkmark Data from a trial in combination with COM701 for platinum resistant ovarian cancer at ESMO-IO 2022
Dec 2022 - Dec 2022: Data from a trial in combination with COM701 for platinum resistant ovarian cancer at ESMO-IO 2022
Checkmark From trial in combination with COM701 for advanced solid tumors
Jun 2021 - Jun 2021: From trial in combination with COM701 for advanced solid tumors
Checkmark From trial in combination with Opdivo for solid tumors at ASCO 2021
More
Completed
1
121
US
COM701, COM701 with Opdivo (Nivolumab).
Compugen Ltd, Bristol-Myers Squibb
Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer
01/24
01/24
rilvegostomig (AZD2936) / AstraZeneca
TROPION-Lung10, NCT06357533: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Recruiting
3
675
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Rilvegostomig, AZD2936, Pembrolizumab, KEYTRUDA
AstraZeneca, Daiichi Sankyo
Non-Small Cell Lung Cancer
04/28
05/30
DESTINY-BTC01, NCT06467357: Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Recruiting
3
620
Europe, Canada, Japan, US, RoW
Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, DS-8201a; T-DXd, Rilvegostomig, Agilent HercepTest™ mAb pharmDx, Ventana PD-L1 SP263 assay
AstraZeneca, Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
Biliary Tract Cancer
06/28
05/29
TROPION-Lung12, NCT06564844: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Recruiting
3
660
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, DS-1062a, Rilvegostomig, AZD2936, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT
AstraZeneca, Daiichi Sankyo
Non-small Cell Lung Cancer
05/33
01/35
NCT06692738: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting
3
880
Europe, Canada, Japan, US, RoW
Rilvegostomig, AZD2936, Pembrolizumab, Keytruda, Carboplatin, Paclitaxel, Nab-paclitaxel
AstraZeneca
Non-small Cell Lung Cancer
02/29
10/29
ARTEMIDE-Lung03, NCT06627647: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Recruiting
3
878
Europe, Canada, Japan, US, RoW
Rilvegostomig, AZD2936, Pembrolizumab, Keytruda, Carboplatin, Cisplatin, Pemetrexed
AstraZeneca
Non-squamous Non-small Cell Lung Cancer
05/29
03/30
ARTEMIDE-Gastric01, NCT06764875: A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Recruiting
3
840
Europe, Canada, Japan, US, RoW
Rilvegostomig, AZD2936, Trastuzumab deruxtecan, T-DXd, DS-8201, Trastuzumab, Pembrolizumab, 5-fluorouracil, 5-FU, Capecitabine, Cisplatin, Oxaliplatin
AstraZeneca
HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
04/29
11/30
DE-01, NCT06989112: DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Trastuzumab deruxtecan, DS-8201a, T-DXd, Rilvegostomig, Pembrolizumab, Keytruda, Carboplatin, Carbomedac, Carbosin, Paraplatin, Paclitaxel, Anzatax, Ebetaxel, Oncotaxel, Paclitax, Paclitaxin, Paxene, Taxol, Docetaxel, Docirena, Taxceus, Taxotere
AstraZeneca, Daiichi Sankyo Co., Ltd., Gynecologic Oncology Group (GOG) Foundation Inc., European Network for Gynaecological Oncological Trial groups(ENGOT)
Endometrial Cancer
01/29
02/31
ARTEMIDELung04, NCT06868277: A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Recruiting
3
830
Europe, Canada, Japan, US, RoW
Rilvegostomig, AZD2936, Pembrolizumab, KEYTRUDA
AstraZeneca
Carcinoma, Non-Small Cell Lung
01/30
12/30
ARTEMIDE-HCC01, NCT06921785: Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Recruiting
3
1220
Europe, Canada, Japan, US, RoW
Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab
AstraZeneca
Hepatocellular Carcinoma
03/29
03/30
ARTEMIDE-Bil01, NCT06109779: Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]
AstraZeneca
Biliary Tract Cancer
06/29
09/30
GEMINI-Hepatobiliary, NCT05775159: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Recruiting
2
260
Europe, Japan, US, RoW
Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine, Cisplatin
AstraZeneca
Hepatocellular Carcinoma, Biliary Tract Cancer
12/25
12/26
NCT06630130: Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Not yet recruiting
2
50
NA
Trastuzumab deruxtecan, Enhertu, Capecitabine, Xeloda, Rilvegostomig, AZD2936
Jeeyun Lee
Stomach Neoplasms
10/28
06/29
NEOLANGIO, NCT06569225: Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA

Not yet recruiting
2
40
Canada
Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
University Health Network, Toronto, Sunnybrook Health Sciences Centre, Hamilton Health Sciences Corporation
Cholangiocarcinoma Resectable
12/27
12/28
TROPION-PanTumor03, NCT05489211 / 2022-000776-19: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours

Jan 2024 - Dec 2024: Data from TROPION-PanTumor03 trial for advanced solid tumors
Recruiting
2
582
Europe, Canada, Japan, US, RoW
Datopotamab deruxtecan (Dato-DXd), DS-1062a, Capecitabine, Xeloda, 5-Fluorouracil, Adrucil, Volrustomig, MEDI5752, Carboplatin, Paraplatin, Leucovorin LV, Folinic acid, Bevacizumab, Avastin, Rilvegostomig, AZD2936, Prednisone/ prednisolone, Prednisolone, Cisplatin, Platinol
AstraZeneca, Daiichi Sankyo
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
08/26
08/26
DESTINY-Gastric03, NCT04379596 / 2019-004483-22: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer

Jul 2023 - Dec 2023: Data from DESTINY-Gastric03 trial for gastric cancer
Checkmark Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020
Jul 2020 - Jul 2020: Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020
Recruiting
2
413
Europe, Canada, Japan, US, RoW
Fluorouracil (5-FU), Capecitabine, Durvalumab, MEDI4736, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, DS-8201a, Cisplatin, Pembrolizumab, Volrustomig, MEDI5752, Rilvegostomig, AZD2936
AstraZeneca, Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
Gastric Cancer
07/26
07/26
GEMINI-Gastric, NCT05702229 / 2022-002840-29: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
2
240
Europe, Japan, US, RoW
Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD7789, AZD0901, 5-Fluorouracil, Capecitabine
AstraZeneca, AstraZeneca AB
Gastric Cancer
07/26
07/27
MERIDIAN, NCT05414032: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

Recruiting
2
200
Canada
AZD2936
University Health Network, Toronto, AstraZeneca, NeoGenomics Laboratories, Inc.
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
07/26
07/26
NeoCOAST-2, NCT05061550 / 2021-003369-37: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Jan 2024 - Dec 2024: Data from NeoCOAST-2 trial for early stage, resectable NSCLC
Recruiting
2
630
Europe, Canada, US, RoW
Durvalumab, MEDI4736, IMFINZI, Oleclumab, MEDI9447, Monalizumab, IPH2201, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, MEDI5752, Rilvegostomig
AstraZeneca, Parexel
Non-small Cell Lung Cancer
05/30
05/30
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
2021-000857-23: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non-small Cell Lung Cancer

Not yet recruiting
1/2
192
Europe
AZD2936, AZD2936, Powder for concentrate for solution for infusion, Concentrate for solution for infusion
AstraZeneca AB, AstraZeneca AB
Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-D)., Non-small Cell Lung Cancer, which is either localized but too big to be removed by surgery (Protocol Parts A-B) or has already spread throughout the body (Protocol Parts A-D)., Diseases [C] - Cancer [C04]
 
 
ARTEMIDE-01, NCT04995523 / 2021-000857-23: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Hourglass Sep 2024 - Dec 2024 : Updated data for advanced/metastatic NSCLC
Recruiting
1/2
210
Europe, Japan, US, RoW
AZD2936, Rilvegostomig
AstraZeneca, AstraZeneca AB
Non-Small-Cell Lung Carcinoma
08/26
03/28
BLUESTAR, NCT05123482: A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

Recruiting
1/2
370
Europe, Canada, Japan, US, RoW
AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)
AstraZeneca
Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
03/27
03/27
ALTAIR, NCT06996782: A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Recruiting
1/2
182
Europe, US, RoW
Rilvegostomig, AZD2936, AB248, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Ramucirumab
AstraZeneca
Advanced or Metastatic Non-small Cell Lung Cancer
12/28
12/28
MAGELLAN, NCT03819465 / 2018-001748-74: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Jan 2024 - Dec 2024: Data from MAGELLAN trial for 1L NSCLC
Active, not recruiting
1
175
Europe, US, RoW
Durvalumab, MEDI4736, Danvatirsen, AZD9150, Oleclumab, MEDI9447, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
AstraZeneca
Metastatic Non-Small Cell Lung Cancer (NSCLC)
05/23
03/26
MST01-AZN-05, NCT06366451: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, AZD9592, Pembrolizumab, Keytruda, MK-3475, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
Presage Biosciences, AstraZeneca
Head and Neck Squamous Cell Carcinoma
02/25
04/25
DESTINY-Lung03, NCT04686305: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Jan 2024 - Dec 2024: Data from DESTINY LUNG03 trial for HER2+ non-squamous NSCLC
Recruiting
1
244
Europe, Canada, US, RoW
T-DXd, DS-8201a, Trastuzumab deruxtecan, Durvalumab, MEDI4736, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Other Name: MEDI5752, Rilvegostomig, Other Name: AZD2936
AstraZeneca, Daiichi Sankyo
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
12/25
12/25
TROPION-Lung04, NCT04612751: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Jan 2024 - Dec 2024: Data from TROPION-Lung04 trial for advanced or metastatic NSCLC
Recruiting
1
371
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, Durvalumab, Imfinzi, Carboplatin, AZD2936, rilvegostomig, MEDI5752, volrustomig, AZD7789, sabestomig
AstraZeneca, Daiichi Sankyo
Advanced or Metastatic NSCLC
01/26
01/26
NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, Merck Sharp & Dohme LLC
Solid Tumor
12/31
12/31
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bapotulimab (BAY 1905254) / Compugen
KEYNOTE-920, NCT03666273: Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

Completed
1
60
US
Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
Bayer, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
06/23
05/24
COM902 / Compugen
CPG-02-101, NCT04354246: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Checkmark Data from trial for solid tumors at SITC 2021
Nov 2021 - Nov 2021: Data from trial for solid tumors at SITC 2021
Checkmark First patient dosed in combination with COM701 in patients with advanced malignancies
Jul 2021 - Jul 2021: First patient dosed in combination with COM701 in patients with advanced malignancies
Active, not recruiting
1
110
US
Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Compugen Ltd
Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
12/25
12/25
COM701 / Compugen
NCT04570839: COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Checkmark Data from a trial in combination with COM701 and BMS-986207 for platinum resistant ovarian cancer at ESMO-IO 2022
Dec 2022 - Dec 2022: Data from a trial in combination with COM701 and BMS-986207 for platinum resistant ovarian cancer at ESMO-IO 2022
Checkmark Data from trial in combination with opdivo for solid tumors at SITC 2021
Nov 2021 - Nov 2021: Data from trial in combination with opdivo for solid tumors at SITC 2021
Checkmark First patient dosed P1/2 study in the triple combination with Opdivo and BMS-986207 for solid tumor
More
Completed
1/2
48
US
COM701 in combination with BMS-986207 and nivolumab.
Compugen Ltd, Bristol-Myers Squibb
Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
05/24
05/24
NCT06888921: A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

Recruiting
1/2
60
US
COM701, Normal Saline
Compugen Ltd
Ovarian Cancer, Ovarian Cancer Recurrent
03/27
03/27
NCT03667716: COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Checkmark Data from a trial in combination with COM701 for platinum resistant ovarian cancer at ESMO-IO 2022
Dec 2022 - Dec 2022: Data from a trial in combination with COM701 for platinum resistant ovarian cancer at ESMO-IO 2022
Checkmark From trial in combination with COM701 for advanced solid tumors
Jun 2021 - Jun 2021: From trial in combination with COM701 for advanced solid tumors
Checkmark From trial in combination with Opdivo for solid tumors at ASCO 2021
More
Completed
1
121
US
COM701, COM701 with Opdivo (Nivolumab).
Compugen Ltd, Bristol-Myers Squibb
Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer
01/24
01/24
rilvegostomig (AZD2936) / AstraZeneca
TROPION-Lung10, NCT06357533: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Recruiting
3
675
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Rilvegostomig, AZD2936, Pembrolizumab, KEYTRUDA
AstraZeneca, Daiichi Sankyo
Non-Small Cell Lung Cancer
04/28
05/30
DESTINY-BTC01, NCT06467357: Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Recruiting
3
620
Europe, Canada, Japan, US, RoW
Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, DS-8201a; T-DXd, Rilvegostomig, Agilent HercepTest™ mAb pharmDx, Ventana PD-L1 SP263 assay
AstraZeneca, Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
Biliary Tract Cancer
06/28
05/29
TROPION-Lung12, NCT06564844: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Recruiting
3
660
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, DS-1062a, Rilvegostomig, AZD2936, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT
AstraZeneca, Daiichi Sankyo
Non-small Cell Lung Cancer
05/33
01/35
NCT06692738: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting
3
880
Europe, Canada, Japan, US, RoW
Rilvegostomig, AZD2936, Pembrolizumab, Keytruda, Carboplatin, Paclitaxel, Nab-paclitaxel
AstraZeneca
Non-small Cell Lung Cancer
02/29
10/29
ARTEMIDE-Lung03, NCT06627647: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Recruiting
3
878
Europe, Canada, Japan, US, RoW
Rilvegostomig, AZD2936, Pembrolizumab, Keytruda, Carboplatin, Cisplatin, Pemetrexed
AstraZeneca
Non-squamous Non-small Cell Lung Cancer
05/29
03/30
ARTEMIDE-Gastric01, NCT06764875: A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Recruiting
3
840
Europe, Canada, Japan, US, RoW
Rilvegostomig, AZD2936, Trastuzumab deruxtecan, T-DXd, DS-8201, Trastuzumab, Pembrolizumab, 5-fluorouracil, 5-FU, Capecitabine, Cisplatin, Oxaliplatin
AstraZeneca
HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
04/29
11/30
DE-01, NCT06989112: DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Trastuzumab deruxtecan, DS-8201a, T-DXd, Rilvegostomig, Pembrolizumab, Keytruda, Carboplatin, Carbomedac, Carbosin, Paraplatin, Paclitaxel, Anzatax, Ebetaxel, Oncotaxel, Paclitax, Paclitaxin, Paxene, Taxol, Docetaxel, Docirena, Taxceus, Taxotere
AstraZeneca, Daiichi Sankyo Co., Ltd., Gynecologic Oncology Group (GOG) Foundation Inc., European Network for Gynaecological Oncological Trial groups(ENGOT)
Endometrial Cancer
01/29
02/31
ARTEMIDELung04, NCT06868277: A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Recruiting
3
830
Europe, Canada, Japan, US, RoW
Rilvegostomig, AZD2936, Pembrolizumab, KEYTRUDA
AstraZeneca
Carcinoma, Non-Small Cell Lung
01/30
12/30
ARTEMIDE-HCC01, NCT06921785: Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Recruiting
3
1220
Europe, Canada, Japan, US, RoW
Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab
AstraZeneca
Hepatocellular Carcinoma
03/29
03/30
ARTEMIDE-Bil01, NCT06109779: Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]
AstraZeneca
Biliary Tract Cancer
06/29
09/30
GEMINI-Hepatobiliary, NCT05775159: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Recruiting
2
260
Europe, Japan, US, RoW
Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine, Cisplatin
AstraZeneca
Hepatocellular Carcinoma, Biliary Tract Cancer
12/25
12/26
NCT06630130: Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Not yet recruiting
2
50
NA
Trastuzumab deruxtecan, Enhertu, Capecitabine, Xeloda, Rilvegostomig, AZD2936
Jeeyun Lee
Stomach Neoplasms
10/28
06/29
NEOLANGIO, NCT06569225: Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA

Not yet recruiting
2
40
Canada
Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
University Health Network, Toronto, Sunnybrook Health Sciences Centre, Hamilton Health Sciences Corporation
Cholangiocarcinoma Resectable
12/27
12/28
TROPION-PanTumor03, NCT05489211 / 2022-000776-19: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours

Jan 2024 - Dec 2024: Data from TROPION-PanTumor03 trial for advanced solid tumors
Recruiting
2
582
Europe, Canada, Japan, US, RoW
Datopotamab deruxtecan (Dato-DXd), DS-1062a, Capecitabine, Xeloda, 5-Fluorouracil, Adrucil, Volrustomig, MEDI5752, Carboplatin, Paraplatin, Leucovorin LV, Folinic acid, Bevacizumab, Avastin, Rilvegostomig, AZD2936, Prednisone/ prednisolone, Prednisolone, Cisplatin, Platinol
AstraZeneca, Daiichi Sankyo
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
08/26
08/26
DESTINY-Gastric03, NCT04379596 / 2019-004483-22: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer

Jul 2023 - Dec 2023: Data from DESTINY-Gastric03 trial for gastric cancer
Checkmark Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020
Jul 2020 - Jul 2020: Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020
Recruiting
2
413
Europe, Canada, Japan, US, RoW
Fluorouracil (5-FU), Capecitabine, Durvalumab, MEDI4736, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, DS-8201a, Cisplatin, Pembrolizumab, Volrustomig, MEDI5752, Rilvegostomig, AZD2936
AstraZeneca, Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
Gastric Cancer
07/26
07/26
GEMINI-Gastric, NCT05702229 / 2022-002840-29: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
2
240
Europe, Japan, US, RoW
Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD7789, AZD0901, 5-Fluorouracil, Capecitabine
AstraZeneca, AstraZeneca AB
Gastric Cancer
07/26
07/27
MERIDIAN, NCT05414032: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

Recruiting
2
200
Canada
AZD2936
University Health Network, Toronto, AstraZeneca, NeoGenomics Laboratories, Inc.
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
07/26
07/26
NeoCOAST-2, NCT05061550 / 2021-003369-37: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Jan 2024 - Dec 2024: Data from NeoCOAST-2 trial for early stage, resectable NSCLC
Recruiting
2
630
Europe, Canada, US, RoW
Durvalumab, MEDI4736, IMFINZI, Oleclumab, MEDI9447, Monalizumab, IPH2201, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, MEDI5752, Rilvegostomig
AstraZeneca, Parexel
Non-small Cell Lung Cancer
05/30
05/30
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
2021-000857-23: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non-small Cell Lung Cancer

Not yet recruiting
1/2
192
Europe
AZD2936, AZD2936, Powder for concentrate for solution for infusion, Concentrate for solution for infusion
AstraZeneca AB, AstraZeneca AB
Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-D)., Non-small Cell Lung Cancer, which is either localized but too big to be removed by surgery (Protocol Parts A-B) or has already spread throughout the body (Protocol Parts A-D)., Diseases [C] - Cancer [C04]
 
 
ARTEMIDE-01, NCT04995523 / 2021-000857-23: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Hourglass Sep 2024 - Dec 2024 : Updated data for advanced/metastatic NSCLC
Recruiting
1/2
210
Europe, Japan, US, RoW
AZD2936, Rilvegostomig
AstraZeneca, AstraZeneca AB
Non-Small-Cell Lung Carcinoma
08/26
03/28
BLUESTAR, NCT05123482: A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

Recruiting
1/2
370
Europe, Canada, Japan, US, RoW
AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)
AstraZeneca
Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
03/27
03/27
ALTAIR, NCT06996782: A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Recruiting
1/2
182
Europe, US, RoW
Rilvegostomig, AZD2936, AB248, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Ramucirumab
AstraZeneca
Advanced or Metastatic Non-small Cell Lung Cancer
12/28
12/28
MAGELLAN, NCT03819465 / 2018-001748-74: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Jan 2024 - Dec 2024: Data from MAGELLAN trial for 1L NSCLC
Active, not recruiting
1
175
Europe, US, RoW
Durvalumab, MEDI4736, Danvatirsen, AZD9150, Oleclumab, MEDI9447, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
AstraZeneca
Metastatic Non-Small Cell Lung Cancer (NSCLC)
05/23
03/26
MST01-AZN-05, NCT06366451: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, AZD9592, Pembrolizumab, Keytruda, MK-3475, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
Presage Biosciences, AstraZeneca
Head and Neck Squamous Cell Carcinoma
02/25
04/25
DESTINY-Lung03, NCT04686305: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Jan 2024 - Dec 2024: Data from DESTINY LUNG03 trial for HER2+ non-squamous NSCLC
Recruiting
1
244
Europe, Canada, US, RoW
T-DXd, DS-8201a, Trastuzumab deruxtecan, Durvalumab, MEDI4736, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Other Name: MEDI5752, Rilvegostomig, Other Name: AZD2936
AstraZeneca, Daiichi Sankyo
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
12/25
12/25
TROPION-Lung04, NCT04612751: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Jan 2024 - Dec 2024: Data from TROPION-Lung04 trial for advanced or metastatic NSCLC
Recruiting
1
371
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, Durvalumab, Imfinzi, Carboplatin, AZD2936, rilvegostomig, MEDI5752, volrustomig, AZD7789, sabestomig
AstraZeneca, Daiichi Sankyo
Advanced or Metastatic NSCLC
01/26
01/26
NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, Merck Sharp & Dohme LLC
Solid Tumor
12/31
12/31

Download Options